来那度胺
多发性骨髓瘤
不确定意义的单克隆抗体病
医学
内科学
地塞米松
恶性肿瘤
单克隆
肿瘤科
沙利度胺
单克隆抗体
免疫学
抗体
作者
S. Vincent Rajkumar,P. Leif Bergsagel,Shaji Kumar
标识
DOI:10.1016/j.hoc.2023.12.001
摘要
Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors , patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM. Patients with newly diagnosed high-risk SMM are candidates for early intervention with lenalidomide or lenalidomide plus dexamethasone for 2 years, or enrollment in clinical trials .
科研通智能强力驱动
Strongly Powered by AbleSci AI